Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition | OncLive
Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.
onclive.com